Donor-specific cytotoxic Τ cell activity was measured over a period of 5 years after transplantation using the cell-mediated lympholysis (CML) test in 124 recipients of unrelated kidney allografts who received conventional immunosuppressive therapy consisting of azathioprine and prednisone. Since patients with a functioning transplant frequently display donor-specific CML nonresponsiveness in vitro, we addressed the question of whether the CML Status has a predictive value regarding the graft prognosis at any time interval until 5 years posttransplantation. Front log-rank type analyses we conclude that the estimated relative risk calculated over the whole follow-up period of a CML-responder in the category of transplant rejectors is 1.25 with 95% confidence bounds between 0.94 and 1.65. Measurements of CML responder Status during follow-up seem to have only limited prognostic value, although the relative risk is borderline significant when the analysis is restricted to the period between 2 weeks and 6 months posttransplantation.
The long-term Immunologie acceptance of a histoincompattble organ graft, which is often assumed to reflect a tolerant State, could be measured in vitro by the use of the cell-mediated lympholysis (CML)* assay Penpheral blood lymphocytes from renal transplant patients with a well-functiomng graft have often been shown to exhibit donor-specific CML-nonresponsiveness (CML-NR) while the CML reactivity against ran domly ehosen stimulator cells usually remams intact (1-7)
The exact mechamsm(s) that underhe the development of such donor specific CML-NR after transplantation are not known, but evidence has been presented that the donor HLA System may regulate this phenomenon (8) Mechamsms that may be mvolved mclude the involvement of suppressor cells (9) (10) (11) (12) (13) (14) , antudiotypic antibodies (25, 16) (13, 20, 21) Since the observations of CML-NR are essentially retrospective evaluations in selective groups of patients, we decided to investigate the predictive value of the CML Status for graft survival Here we present the results of 372 donor-specific CML studies in 124 renal transplant recipients in relation to allograft survival
MATERIALS AND METHODS

Patients
PBLs from 124 renal patients who had received a first cadavenc renal transplant through the Services of Eurotransplant were investigated for their cytolytic potential against donor splenocytes as well as against control cells From 69 patients additional pretransplant PBLs were available for study All patients had received one or more blood transfusion(s) beiore transplantation Immunosuppression con sisted of prednisone and azathiopnne Transplantation was considered successful if the recipient remained alive without (re)institution of dialysis Patients who rejected their graftb were studied till graft ne phrectomy
In vitro studies Senal samples of recipients' PBLs were collected at several intervals up to 5 years after transplantation The time mtervals of blood sample collection and the total number of samples (average 4, maximum 13) available for study vaned for each patient The PBLs (ι e 10° responder cells) were sensitized in vitro for 6 days against 10 8 irradiated splenocytes from the specific kidney donor as well as against 10 6 control cells from healthy unrelated individuals Depending on the amount of lymphocytes available, which was limited in most of the cases, either tissue culture flasks or 2 ml cluster wells were used, the ratio responder/stimulator celi however is identical in both culture conditions After the culture period, the effector cells were harvested and tested in the Standard CML assay against their specific stimulator cells (ι e splenocytes of the specific kidney donor and control cells of healthy unrelated individuals) as target cells Donor lymphocytes were obtained from the spieen All patients' blood samples, the donor spieen cells, and the control cells were frozen and stored in hquid nitrogen until used CML NR or CML R These terms are used to descnbe the CML nonresponsiveness or CML responsiveness, respectively, exhibited by the recipients' PBLs against the specific kidney donor splenocytes Almost all the recipients showed a normal cytolytic response to HLA incompatible control cells The few cases in which the response to the control cells remained low in repeated expenments were excluded from the analyses
The CML assay has been described in detail (22) The percentages of lysis were determmed using phytohemagglutimn stimulated blast cells in a 4 hr 'Cr assay Cytotoxicity (i e the amount of isotope released from 51 Cr labeled target cells) was determmed and calculated according to the described method (22) Standard errors of the mean of triplicate determinations were less than 5% Positive and negative assignments were made on the basis of a 10% specific 51 Cr release value and on a positive slope, ι e the vanous effector to target cell ratios are plotted and must give an S shaped curve (or in the case of transforimng the percentage of lysis to a log scale a straight hne) All experiments were repeated at least twice at different effector to target cell ratios Statistwal analyses In order to assess the association between CML responder status during follow up and subsequent graft failure, a log rank type analysis was performed followmg the method outhned by Mantel and Byar (23) At each time point t (days posttransplantation) on which one or more failures occurred, the group of patients at nsk was divided into two groups, CML NR or CML R, according to their last CML test done before time t (Patients without CML test before time t were considered to be not at nsk) Next, for each group the expected numbers of failures (under the hypothesis that the probabihty of failure does not depend on the CML Status) were computed in the usual way Then expected and observed numbers of failures were compared analogously to the procedure of the Standard log rank test Two analyses were carned out In the first one the endpoint was graft failures from all causes mcluding death of the patient In the second analysis the endpoint was acute rejection Observations of graft iailures with another cause and observations of patients who died with a functioning graft were treated as censored in this analysis
RESULTS
Longitudinal CML studies up to 5 years after transplantation were performed with the lymphocytes from 124 patients who had received a kidney transplant from an unrelated donor Three examples of serial investigations are shown in Figure 1 The penod m which the CML responder status may convert from positive to negative differs between individuals, as exem phfied in Figure 1 Patient 1 (CML-NR) 2  6  7  12  13  14  15  19  20  21  34  36  37  40  42  80  89  95  104  110  133  153  177  376  438  562  627  739  748  810  830  871  912  1214  1243  1758  2007  2073  2205  2241  2421   Total"   19  24  25  30  31  31  31  32  31  32  33  33  32  32  32  30  30  30  30  29  35  35  36  49  53  59  60  67  67  69  69  69  68  68  64  47  44  44  43 60  55  53  52  50  49  48  46  46  44  42  41  41  40  39  40  39  37  36  36  32  31  30  25  22  19  20  19  18  18  18  19  19  19  18  19  18  17  15  15 " Log rank analysis calculated over the whole follow up penod vield = 0 13 ' CML status according to the last previous measurement In order to assess the relationship between CML status during follow up and the nsk of graft failure, the log rank analysis was carned out Table 1 shows the observed and expected numbers of failures according to CML status at each time that a failure occurred Although a trend is vjsible (on average more rejecüons observed than expected in CML R patients), we could not accept the hypothesis that CML R patients have more graft failures than CML NR (P = 0 13) The Mantel Haenszel estimate of the relative nsk (CML R versus CML-NR) was 1 25 with 95% confidence mterval of 0 94-1 65 Since most renal transplants are lost because of acute rejection in the first 6 months after transplantation {24), we carried out the same analysis for this time traject The results shown in Table 2 demonstrate that the number of graft rejections in the CML R group IS higher than expected on the basis of random distribution of rejection cases between CML-NR and CML-R patients The effect is most prominent in the penod between 2 weeks to 6 months posttransplantation, which just reached statistical significance (P = 0 052)
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The statistical analysis as shown above was done based on the Information that the graft was either "functioning" or "nonfunctiomng " Therefore "nonfunctioning" grafts included acute rejections, which were about two thirds of all failures, recurrent original disease, chromc rejection, death of the pa tient, or other not further-identified causes of failures Conse quently, the same statistical analysis was carried out on functionmg renal allografts versus acute rejections only This analy sis as shown in Table 3 demonstrates that although a trend is observed similar to the results of the analysis compnsmg all "nonfunctioning" grafts (Table 2) , the data fall to reach statis tical significance (P = 0 085, posttransplant penod 15-153 days)
We also investigated whether the pretransplant CML Status has predictive capabihty for the hkelihood of posttransplant development of CML-NR The availabihty of pretransplant blood samples of 69 recipients provided the Information con cerning the donor-directed CTL reactivity prior to grafting Fifty one recipients showed CML reactivity against the splenocytes of the kidney donor Twenty eight of 51 patients who exhibited pretransplant CML reactivity developed donor-specific CML nonreactivity at different times posttransplant, whereas 23 patients persistently demonstrated donor-directed CTL activity, 15 pretransplant CML NR patients remained CML NR posttransplantation Three patients with acute irre versible rejection showed "reversed" CML conversion absence of pretransplant donor directed CTL activity but high levels of cytotoxic activity shortly after grafting pnor to graft nephrectomy Acute irreversible graft rejection was observed within 7, 12, and 15 days, respectively, this "reversed conversion" of CML NR pretransplant to CML-R posttransplant might appear to be an indication for poor graft survival
DISCUSSION
In vitro donor specific cell-mediated lympholysis nonresponsiveness exhibited by cells from recipients with well-functionmg kidney allografts is a generally observed association (1-7) . All studies except one (6) were carried out with a short-time follow-up Notwithstanding these observations, we assessed to what extent this apparent m vitro reflection of acqmred tolerance can be explained by selection for patients who get the chance to develop CML-NR The availabihty of over 350 CML studies in 124 renal transplant patients with a follow-up penod of approximately 5 years enabled us to investigate whether the CML NR predicts graft survival durmg follow-up By assessing the correlation of the outcome of the CML tests and graft survival for different time intervals, lt appeared that only the posttransplant penod between 2 weeks and 6 months showed a (marginally) significant correlation (P = 0 05) between CML-NR and graft survival on one hand, and CML-R and graft lost on the other hand; the data failed however to reach statistical significance when analyzmg only the acute rejections (P = 0 085, Table 3 ) Nevertheless, these trends could be of mterest in view of the chnical observation that most acute rejection episodes occur within this time penod (24) The results obtained with the 69 patients senally momtored from pre-to posttransplantation demonstrated that pretransplant donor-directed CTL activity is not a contraindication for transplantation and does not preclude the development of CML NR posttransplantation Conversely, pretransplant CML-NR con verting shortly after transplant to CML-R was in 3 out of 3 cases associated with acute rejection and graft loss It also appeared from our studies that several patients had a well-functioning graft while demonstrating in vitro donor-specific CML activity, hkewise a number of patients rejected their graft despite their CML-NR Status The Situation in which patients with a well-functioning graft show in vitro donorspecific CML activity is compatible witb the experimental animal studies in which specific cytotoxic Τ cells were found m nonrejected rat kidneys (25) The cellular mechanism of graft destruction is probably composed of phenotypically and functionally different Τ cell subsets directed against MHC class I and class II transplantation antigens, as was recently reported by Miceh et al (26) and by Bonneville et al (27) These observations are consistent with the findmgs that cytotoxic Τ effector cells are not the sole mediators of graft rejection as was first observed by Loveland et al (28) Although these and numerous experimental animal studies that followed (29), which were designed to unravel the effector mechamsms of allograft rejection, concern skin grafting in nonimmune suppressed animals, they provide important msights mto the com piexity of Immunologie responses in human allograftmg. Effector mechamsms operatmg in vascularized human allograft rejection are also dependent on the genetic constitution of the recipient (30) Prehminary results of this ongoing study show that lf the transfusion donor and recipient are mismatched for both HLA-DR antigens, the recipient IS immunized resulting in a transient increase of cytotoxic activity, after an HLA DR shared transfusion, the in vitro test remained unchanged or shghtly decreased. However in none of cases studied so far, has lt led to CML-NR Α method of monitoring the graft certamly is to perform graft biopsies (36) or fine-needle aspirates (37) The in vitro monitoring by measurement of the donor-directed cytotoxic Τ cell activity as described herein may provide further Information regardmg acute rejection Although predictions regardmg the likehhood of the occurrence of posttransplant CML-NR must be made with great caution, posttransplant monitoring usmg the CML assay may at least for the first 6 months after transplantation be helpful for the Interpretation of chnical events and possibly for the design of therapeutic strategies Acknowledgments The authors thank Prof Dr R Α Ρ Koene, Dr J Μ Wilmink, and Dr W Weimar, whose patients were mcluded in the mvestigations, and Mrs I Cunel and Mrs Ε van der Willik for editing the manuscnpt In order to study the effect of corticosteroids on energy metabolism in immunosuppressed patients after kidney transplantation, we have examined glucose utilization, energy expenditure, and lean body mass in 10 kidneytransplanted patients receiving steroids (methylprednisolone 8.2±1.5 mg/day) and in 10 healthy age-and weight-matched control subjects. Glucose utilization was measured during euglycemic insulin clamp in combination with indirect calorimetry and infusion of [ 3 H-3]-glucose, while /?-cell function was measured during a hyperglycemic clamp. The kidney-transplanted patients were resistant to the glucoregulatory effect of insulin, as demonstrated by a 25% reduction in total glucose disposal compared to control subjects. This defect was almost completely accounted for by a defect in storage of glucose as glycogen (3.3±0.5 vs. 5.0+0.5 mg/kgLBMmin; P<0.05). The reduction in nonoxidative glucose disposal was associated with reduced lean body mass and incapacity to release energy as heat after infusion of insulin, i.e. thermogenic defect. In contrast, oxidation of glucose and Iipids was not influenced by steroid therapy. Futhermore, suppression of hepatic glucose production was normal, and insulin secreiion was normally enhanced in relation to the degree of insulin resistance in the steroid-treated patients. In conclusion, steroidinduced insulin resistance in kidney-transplanted patients is due to alterations in the nonoxidative pathway of glucose metabolism. These findings raise the question
